The effectiveness of melatonin in coronary heart disease
https://doi.org/10.30629/0023-2149-2022-100-6-285-287
Abstract
The article is dedicated to a review of the literature on the use of melatonin in patients with coronary artery disease, taking into account its participation in the regulation of the cardiovascular system, the function in the presence of a circadian rhythm of hemodynamic parameters and melatonin receptors in the muscular layer and endothelial tissue. The eff ect of melatonin on the organs of the cardiovascular system is due to its pronounced antioxidant activity, and the ability to infl uence vascular tone, heart rate, and inhibit platelet aggregation.
Keywords
Supporting agencies: The study had no sponsorship
About the Author
R. M. Zaslavskaya
Russian Academy of Science
Russian Federation
Russian Federation
Rina M. Zaslavskaya
Cosmic Research Istitute
117485
Moscow
References
1. Малиновская Н. К. Мелатонин и сердечно-сосудистая система / Н. К. Малиновская [и др.] // Мелатонин в норме и патологии. – М., 2004. – С. 85–101. [Malinovskaya N. K. et al. Melatonin and cardiovascular system. Melatonin in norm and pathology. 2004: 85–101. (In Russian)].
2. Grossman E. et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am. J. M. 2006; 119 (10): 898–902.
3. Cuzzocrea S. et al. Pharmacological action of melatonin in shock, inflammation and ischemia/reperfusion injury. Eur. J. Pharmacol. 2001; 426 (1–2): 1–10.
4. Salie R. et al. Protects Against ischemic reperfusion myocardial damage. J. Mol. Cell. Cardiol. 2001; 33 (2): 343–357.
5. Zaslavskaya R. M. et al. Melatonin, refractory hypertension, myocar dial ischemia and other challenges in nightly blood pressure lowering. Biomed. Pharmac. 2004; 58 (1): 129–134.
6. Lee Y. M. et al. Protective eff ects s of melatonin on myocardial ischemia/reperfusion in vivo. J. Pineal. Pes. 2002; 33 (2): 98–106.
7. Vacas M. I. et al. Inhibition of human platelet aggregation and thromboxane B2 production by melatonin. Correlation with plasma melatonin level. J. Pineal. Ress. 1991; 11 (3–4): 135–139.
8. Sewerynek E. Melatonin and the cardiovascular system. Neuro Endocrinol. Left. 2002; 23 (1): 79–83.
9. Коваленко Р. И. Эпифиз в сиcтеме нейроэндокринной регуляции / Р. И. Коваленко // Основы нейроэндокринологии. – СПб., 2005. – С. 337–365. [Kovalenko R. I. Epiphysis in the neuroendocrine regulation system. Basis of neuroendcrinology. SPb., 2005: 337–365. (In Russian)] .
10. Altun A. et al. Impraired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci. Lett. 2002; 327 (2): 143–145.
11. Girotti L. Low urinary 6-sulphatoxymtlatonin levels in patients with coronary artery disease. J. Pineal. R. 2000; 29 (3): 138–142.
12. Sakotnik A. et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur. Heart J. 1999; 20 (18): 1314–1317.
13. Zaslavskaya R. M., Lilitsa G. V. Infl uence of melatonin on the oxidative stress and hemodynamics in old patients with heart failure. Proceed. of an international conference. Graz. Austria. 2004; 17 (4): 507.
14. Mjonas et al. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press. 2003; 12 (1): 19–24.
15. Безпятых А. Ю. Мелатонин: теория и практика / А. Ю. Безлятых [и др.] – М.: Медпрактика-М, 2009. – С. 100. [Bespyatych A. Y. et al. Melatonin: theory and practice. M., Medpractika-M, 2009; 100. (In Russian)].
16. Рапопорт С. И. Мелатонин и регуляция деятельности сердечно-сосудистой системы / С. И. Рапопорт, А. М. Шатапова // Клиническая медицина. – 2001. – 79 (6): 4–7. [Rapoport S. I., Shatapova A. M. Melatonin and cardiovascular regulation. Clin. Medicine. 2001; 79 (6): 4–7. (In Russian)].
17. Martin F. J. et al. Melatonin eff ect on serotonin uptake and release in rat platelets diurnal variation in responsiveness. Life Sci. 1993; 53 (13): 1079–1087.
18. Бакшеев В. И. Мелатонин в системе нейрогуморальной регуляции у человека. Ч. 1. Клиническая медицина / В. И. Бакшеев, Н. М. Коломиец. – 2011. – 89 (1–10): 1079–1087. [Baksheev V. I., Kolomiets N. M. Меlatonin in system of neuroregulation in men. Part 1. Clin. Medicine. 2011; 89 (1–10):1079–1087. (In Russian)].
19. Залвеян П. А. Суточный ритм артериального давления: клиническое значение и прогностическая ценность / П. А. Залвеянм [и др.] // Кардиология. – 2002. – 2 (10). – С. 55–61. [Zalveyan P. A. et al. Daily rhythm of arterial pressure: clinical meaning and prognosis value. Cardiology. 2002; 2 (10): 55–61. (In Russian)].
20. Труфакин В. А. Проблемы центральной регуляции биоритмов иммунной системы. Роль экзогенного и эндогенного мелатонина / В. А. Труфакин, А. В. Шарлыгина // Вестник РАМН. – 2006. – 9–10. – С. 121–127. [Trufakin V. A., Sharligina A. V. Problems of central regulation in biorhythms of immune system. Role of exogen and endogen melatonin. Bulletin RAMN. 2006; 9–10:121–127. (In Russian)].
21. Cagnacci A. et al. Prolonged melatonin administration deceases nocturnal blood pressure in women. Am. J. Hypertens. 2005; 18 (12): 4–1618.
22. Заславская Р. М. Роль мелатонина в лечении больных сердечно-сосудистыми заболеваниями / Р. М. Заславская [и др.] // Хронобиология и хрономедицина: руководство. – М., 2012. – С. 363–378. [Zaslavskaya R. M. et al. Role of melatonin in therapy of patients with cardio-vascular diseases. Chronobiology and chronomedicine: leadership. M., 2012: 363–378. (In Russian)].
23. Кветная Т. В. Мелатoнин как биологический маркер опухолевого роста / Т. В. Кветная [и др.] // Мелатонин в норме и патологии. – М., 2004. – С. 285–304. [Kvetnaya T. V. et al. Melatonin is a biological marker of tumor growth. Melatonin in norm and pathology. М., 2004: 285–394. (In Russian)].
24. Заславская Р. М. Влияние мелатонина на циркадианную организацию артериального давления и частоты сердечных сокращений у больных стабильной стенокардией в сочетании с артериальной гипертензией : Тез. докл. Всероссийской научно-практич. конф / Р. М. Заславская [и др.] – СПб., 2008. – С. 15–16. [Zaslavskaya R. M. et al. Influence of melatonin on circadian organization of arterial pressure and frequency of cardiac contractions in patients with stable stenocardia along arterial hypertension. Abstracts of reports science-practic. conf. SPb., 2008: 15–16. (In Russian)].
25. Заславская Р. М. Мелатонин в комплексном лечении больных стабильной стенокардией и артериальной гипертонией / Р. М. Заславская, Э. А. Щербань, С. И. Логвиненко // Клиническая медицина. – 2008. – 86 (9). – С. 64–67. [Zaslavskaya R. M., Shcherban E. A., Logvinenko S. I. Melatonin in complex therapy of patients with stable stenocardia and arterial hypertension. Klinicheskaya meditsina. 2008; 86 (9): 64–67. (In Russian)].
26. Кветная Т. В. Мелатонин — нейроиммуноэндокринный маркер возрастной патологии / Т. В. Кветная, И. В. Князькин, И. М. Кветной. – Санкт-Петербург: ДИАН, 2005. – 142 с.. [Kvetnaya T. V., Knyaskin I. V., Kvetnoy I. M. Melatonin is a neuroimmunoendocrine marker of agerelated pathology. St. Petersburg. DIAN, 2005: 142. (In Russian)].
27. Ekmekcioglu C. et al. The melatonin receptor subtype MT2 is present in the human cardiovascular system. J. Pineal Res. 2003; 35 (1): 40–44.
28. Vazan R. et al. Melatonin and the heart. Cesk. Fisiol. 2004; 1: 29–33.
29. Yildxiz M., Akdemir O. Assessment of the effects of physiological release of melatonin on arterial distensibility and blood pressure. Cardiol. Young. 2009; 19 (2): 198–203.
30. Koslovski E. et al. Melatonin stimulates release of tissue factor pathway inhibitor from the vascular endothelium. Blood Coagul. Fibrinolysis. 2011; 22 (4): 254–259.
31. Silli A. et al. Melatonin serum levels in rheumatoid arthritis. Ann. N-Y. Acad. Sci. 2002; 966: 276–283.
Review
For citations:
Zaslavskaya R.M. The effectiveness of melatonin in coronary heart disease. Clinical Medicine (Russian Journal). 2022;100(6):285-287. (In Russ.) https://doi.org/10.30629/0023-2149-2022-100-6-285-287
Views:
3547
Email this article 